Is LMAT a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Price, not volume, is the growth engine, with revenue (ttm) at ~$262M, up ~12% year over year. The bear case rests on cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. Analysts covering it are spread from $81.00 to $132.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $81.00, -1.7% from the $82.38 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Price, not volume, is the growth engine. Q2 2026 organic growth of ~10% broke down as ~7% price and ~3% units. The most optimistic analyst target on LMAT is $132.00, +60.2% from the $82.38 price. That figure is only reachable if this thesis works close to its best case.

Cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. The North Brunswick, New Jersey facility, where the Artegraft graft that now carries ~21% of sales is processed, received additional FDA quality-system observations on June 25, 2026, with a company response filed July 16; an escalation there would reach a large share of revenue. Separately, an FDA pre-submission indicated a clinical trial is likely to be required for the QuickStitch product, on timelines measured in years, and catheter sales fell ~11% against a prior-year period inflated by post-recall stocking orders. Currency, Middle East export disruption and the tissue constraint each accounted for roughly a third of the Q2 revenue shortfall and are expected to persist through the second half. The convertible notes convert near ~$119 to ~$120 per share, which caps upside participation with dilution above that level; as of August 2026 no filed securities class action, restatement or going-concern matter appears in the company's filings, and the stock's ~28 times forward earnings leaves limited room if pricing power narrows. The most pessimistic published target is $81.00, -1.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

LeMaitre Vascular sells the hardware of open vascular surgery: biologic patches, bovine carotid grafts, shunts and catheters, mostly to hospital vascular teams.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Price, not volume, is the growth engine) stalling in the reported numbers rather than in the narrative, the risk above (cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Devices and implants for open vascular surgery: bovine carotid artery grafts (Artegraft), biologic patches, human vascular and cardiac allografts, carotid shunts, valvulotomes, embolectomy catheters and synthetic grafts. About 163 direct representatives sell them to vascular surgeons rather than through distributors in most major markets.

Yes, and unusually so for its size. The June 2026 quarter produced ~$20.4M of operating income on ~$70.4M of sales, a ~29% operating margin, with a ~72.1% gross margin and ~$17.1M of net income. Trailing twelve-month net income is ~$65.7M on ~$262M of revenue.

It pays ~$0.25 per quarter, or ~$1.00 annualized, a yield of roughly 1.2% at ~$82 a share. The board raised the dividend 25% in February 2026. A separate $100M repurchase authorization runs through February 18, 2027 and had not been used as of the June 2026 quarter.